Russian River Health Center Bldg #2 Annex Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Not Enrolled in Medicare Practice Location: 16312 Third St, Guerneville, CA 95446 Phone: 707-869-5977 Fax: 707-869-5976 |
Russian River Health Center Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Medicare Enrolled Practice Location: 16387 First St, Guerneville, CA 95446 Phone: 707-869-2849 Fax: 707-869-1477 |
West County Health Centers, Inc Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Not Enrolled in Medicare Practice Location: 16319 Third Street, Guerneville, CA 95446 Phone: 707-869-5977 Fax: 707-869-5983 |
Russian River Health Center Building #2 Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Medicare Enrolled Practice Location: 16312 Third Street, Guerneville, CA 95446 Phone: 707-869-2933 Fax: 707-869-2663 |
West County Health Centers, Inc. Clinic/Center - Federally Qualified Health Center (FQHC) Medicare: Not Enrolled in Medicare Practice Location: 16385 First St., Guerneville, CA 95446 Phone: 707-869-2849 |
News Archive
OSI Systems, Inc. (NASDAQ: OSIS), a vertically integrated provider of specialized electronic products for critical applications in the Security and Healthcare industries, today announced that its Healthcare division, Spacelabs Healthcare, has received a follow-on contract for a broad range of patient monitoring products from a major U.S. regional hospital totaling approximately $2 million.
The Mexican company "Medical and Surgical Center for Retina" created a way to transport drugs, in order to avoid risks and painful treatments in people with secondary blindness due to chronic degenerative blindness such as diabetic retinopathy and degeneration of the eye.
The benefits of physical activity may outweigh the impact of overweight and obesity on cardiovascular disease in middle-aged and elderly people, according to research published today in the European Journal of Preventive Cardiology.
Lixisenatide (trade name: Lyxumia) has been approved in Germany since February 2013 for the treatment of type 2 diabetes mellitus in combination with oral blood-glucose lowering drugs or basal insulin when these, together with diet and exercise, do not provide adequate glycaemic control. In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products, the German Institute for Quality and Efficiency in Health Care examined whether this new drug offers an added benefit over the current standard therapy.
As the eyes of the world turn to Rio de Janiero for the 2016 Summer Olympics, the spread of the Zika virus in Brazil is a growing concern — but Zika is not the only disease that mosquitoes can spread to humans.
› Verified 1 days ago